The role of therapeutic leukapheresis in hyperleukocytotic AML.
Hyperleukocytosis in AML with leukostasis is a serious life-threatening condition leading to a high early mortality which requires immediate cytoreductive therapy. Therapeutic leukapheresis is currently recommended by the American Society of Apheresis in patients with a WBC>100 G/l with signs of...
Main Authors: | Friederike Pastore, Alessandro Pastore, Georg Wittmann, Wolfgang Hiddemann, Karsten Spiekermann |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3986260?pdf=render |
Similar Items
-
The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
by: Friederike Pastore, et al.
Published: (2014-01-01) -
Leukapheresis and Hyperleukocytosis, Past and Future
by: Zhang D, et al.
Published: (2021-07-01) -
Therapeutic leukapheresis in a tertiary care hospital: A case series
by: Raj Nath Makroo, et al.
Published: (2017-01-01) -
Emergency therapeutic leukapheresis in a case of acute myeloid leukemia M5
by: Ranganathan Sudha, et al.
Published: (2008-01-01) -
MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
by: Naidu M. Vegi, et al.
Published: (2016-07-01)